Pediatric Psoriasis Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Pediatric Psoriasis Market: By Type (Plaque Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Inverse Psoriasis, Erythrodermic Psoriasis, Mucosal/oral Psoriasis, Nail Psoriasis, Napkin or Diaper Psoriasis, Photosensitive Psoriasis, and Flexural Psoriasis), Treatment (Topical therapy, Oral, Injections, Biologics, Natural supplements, and Phototherapy), End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, and Research Organizations) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Pediatric Psoriasis Market size is valued at USD 11,372.8 million in 2021 and is expected to grow at a CAGR of 8.7% during the forecast period 2022-28. Psoriasis is an autoimmune inflammatory disorder that causes excessive skin cell production, resulting in an itchy, painful skin condition characterized by inflammation, red lesions, and plaque formation. There are mainly two types of psoriasis: plaque psoriasis and psoriatic arthritis (PsA). According to a study published by Celgene Corporation, around 30.0% of patients suffering from the illness develop psoriatic arthritis, which is an inflammation of the joints. The rapidly growing neonatal population born with autoimmune disease, rising prevalence of plaque and psoriatic arthritis, a large pipeline of biologic and biosimilar products, favorable reimbursement policies, and rising biologic product prescription volume are all major factors driving the pediatric psoriasis market growth in the forecast period. According to the National Psoriasis Foundation (NPF), there will be around 125 million psoriasis patients worldwide in 2021. Approximately 14.8% to one-third of all psoriasis cases occur by the age of 15, making this illness a severe global problem. The prevalence of this ailment ranges from 1.5 to 5.0% in most developed countries, with an upward trend linearly from the age of 1-year-old to 18 years old in disease prevalence observed in recent years. The rising incidence of psoriasis around the world has created a significant demand for safe and effective treatment options. Which can be predicted to boost the pediatric psoriasis market size in the prophecy period. For example, according to U.S. Census data, the reported number of cases in the United States in 2021 was roughly 8 million. In addition, MedPage Today, LLC. article published in November 2021 stated that a six-month delay in diagnosing psoriatic arthritis could result in joint erosions, damage, and incapacity. Furthermore, with a thorough analysis of the pediatric psoriasis market insight, it can be estimated that with a recent wave of biologicals in the treatment of psoriatic diseases, FDA approvals of new drugs are predicted to shape the pediatric psoriasis market growth more than expected by the end of 2028, leveraging a considerable market potential for investment in novel product development and clinical trials. Psoriasis is a chronic condition that costs a great deal of money to treat. According to the financial evaluation for psoriasis therapy, medicine expenditures account for around 20.0% of overall costs. According to the NPF, one in every three individuals suffering from the disease has difficulty paying for therapy, and a tube of topical drugs may cost between USD 500 and USD 600. Furthermore, biologics could cost between USD 15,000 and USD 20,000 per year. Thus, despite increased disease prevalence, high medicine prices for treatment and a lack of favorable reimbursement policies in emerging nations are the primary factors limiting market growth over the forecast period.

 

Key Developments in the Pediatric Psoriasis Market:

In July 2022, Arcutis wins FDA endorsement for Zoryve cream in psoriasis treatment in both children and adults

In June 2021, FDA approved Novartis Cosentyx for moderate to severe psoriasis in children and adolescents.

In April 2020, Eli Lilly’s Ixekizumab was approved for pediatric plaque psoriasis treatments.

Pediatric Psoriasis Market

MARKET SUMMARY
-
8.7%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 8.7%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Pediatric Psoriasis Market

  • The global pediatric psoriasis market report gives a comprehensive outlook across the globe with particular emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
  • The report on the global pediatric psoriasis market gives historical, current, and future market sizes based on type, treatment, end user, and geography
Key Players
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Celgene Corporation
  • Johnson & Johnson
Pediatric Psoriasis Market Dynamics

According to the pediatric psoriasis market research report by PBI, the global pediatric psoriasis market is expanding rapidly as a result of rising demand for disease therapy, such as pediatric psoriasis, and favorable government initiatives which are being followed by active product development. Treating a child with psoriasis has been a tremendous difficulty due to aspects such as physical development and pace of cutaneous absorption. With the advancement of technology, research has made major contributions to the creation of many disease treatments around the world. Psoriasis is a debilitating condition that affects children emotionally and physically, as well as in other parts of their lives. When considering phototherapy in youngsters for the rest of their lives, prolonged sun exposure makes it more difficult. As a result, long-term psoriasis treatment with phototherapy or medicines requires careful consideration. Researchers are also working on pediatric psoriasis research in emerging economies, which presents an untapped potential for the pediatric psoriasis market growth throughout the projection period. There are very few approved therapeutic options for infantile psoriasis in the child population. Furthermore, prominent market competitors are taking critical steps to increase their product offerings in order to broaden treatment alternatives. According to the Indian Society of Pediatric Dermatology, the prevalence is projected to rise with age, reaching roughly 0.55% in children aged 0 to 9 years. Furthermore, pharmaceutical and biopharmaceutical firms predict rapid market expansion in the near future.


North-America Got Significant Share

Pediatric Psoriasis Market

In terms of revenue, North America accounted for the maximum 34.5% market share in the Pediatric Psoriasis market and is predicted to expand at a CAGR of 8.8% during the forecast period. This increase can be attributed to the increasing use of Pediatric Psoriasis. Because of the presence of key Pediatric Psoriasis companies in economies such as Japan and China, the market in APAC is expected to grow significantly and to register a CAGR of 9.0% in the coming years. Europe was the second-largest market and is predicted to grow at a rapid pace throughout the forecast period. The rising frequency of the condition in European countries has boosted demand for medicinal medications, accelerating regional market expansion. According to data given by the National Institute for Health and Care Excellence (NICE), the prevalence of the illness in the general population in the United Kingdom is estimated to be between 1.3% and 2.2%.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The pediatric psoriasis market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Pediatric Psoriasis Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The pediatric psoriasis market is projected to expand at a CAGR of 8.7% during the forecast period

AbbVie Inc., Amgen Inc., Eli Lilly & Company, AstraZeneca, Celgene Corporation, Johnson & Johnson

North America is the fastest-growing region for the pediatric psoriasis market


Report

Table Of Content

1. Executive Summary
2. Global Pediatric Psoriasis Market Introduction
2.1. Global Pediatric Psoriasis Market – Taxonomy
2.2. Global Pediatric Psoriasis Market –Definitions
2.2.1. By Type
2.2.2. By Treatment
2.2.3. By End User
2.2.4. By Region
3. Global Pediatric Psoriasis Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Pediatric Psoriasis Market Dynamic Factors – Impact Analysis
3.6. Global Pediatric Psoriasis Market – Competition Landscape
3.7. Epidemiology
4. Global Pediatric Psoriasis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Pediatric Psoriasis Market, By Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Plaque psoriasis
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Guttate psoriasis
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Pustular psoriasis
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Inverse psoriasis
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Erythrodermic psoriasis
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Mucosal/oral psoriasis
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Nail psoriasis
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Napkin or diaper psoriasis
5.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Photosensitive psoriasis
5.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.10. Flexural psoriasis
5.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
6. Global Pediatric Psoriasis Market, By Treatment, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Topical therapy
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Oral
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Injections
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Biologics
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Natural supplements
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Phototherapy
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Pediatric Psoriasis Market Forecast, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. Hospitals
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Research Organizations
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Ambulatory Care Centers
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Research Organizations
7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Pediatric Psoriasis Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Pediatric Psoriasis Market – Opportunity Analysis Index, By Type, By Treatment, By End User, and Region, 2022 – 2028
9. North America Pediatric Psoriasis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Plaque psoriasis
9.1.2. Guttate psoriasis
9.1.3. Pustular psoriasis
9.1.4. Inverse psoriasis
9.1.5. Erythrodermic psoriasis
9.1.6. Mucosal/oral psoriasis
9.1.7. Nail psoriasis
9.1.8. Napkin or diaper psoriasis
9.1.9. Photosensitive psoriasis
9.1.10. Flexural psoriasis
9.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Topical therapy
9.2.2. Oral
9.2.3. Injections
9.2.4. Biologics
9.2.5. Natural supplements
9.2.6. Phototherapy
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospitals
9.3.2. Research Organizations
9.3.3. Ambulatory Care Centers
9.3.4. Research Organizations
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Pediatric Psoriasis Market – Opportunity Analysis Index, By Type, By Treatment, By End User and Country, 2022 – 2028
9.6. North America Pediatric Psoriasis Market Dynamics – Trends
10. Europe Pediatric Psoriasis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Plaque psoriasis
10.1.2. Guttate psoriasis
10.1.3. Pustular psoriasis
10.1.4. Inverse psoriasis
10.1.5. Erythrodermic psoriasis
10.1.6. Mucosal/oral psoriasis
10.1.7. Nail psoriasis
10.1.8. Napkin or diaper psoriasis
10.1.9. Photosensitive psoriasis
10.1.10. Flexural psoriasis
10.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Topical therapy
10.2.2. Oral
10.2.3. Injections
10.2.4. Biologics
10.2.5. Natural supplements
10.2.6. Phototherapy
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospitals
10.3.2. Research Organizations
10.3.3. Ambulatory Care Centers
10.3.4. Research Organizations
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Pediatric Psoriasis Market – Opportunity Analysis Index, By Type, By Treatment, By End User and Country, 2022 – 2028
10.6. Europe Pediatric Psoriasis Market Dynamics – Trends
11. Asia-Pacific Pediatric Psoriasis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Plaque psoriasis
11.1.2. Guttate psoriasis
11.1.3. Pustular psoriasis
11.1.4. Inverse psoriasis
11.1.5. Erythrodermic psoriasis
11.1.6. Mucosal/oral psoriasis
11.1.7. Nail psoriasis
11.1.8. Napkin or diaper psoriasis
11.1.9. Photosensitive psoriasis
11.1.10. Flexural psoriasis
11.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Topical therapy
11.2.2. Oral
11.2.3. Injections
11.2.4. Biologics
11.2.5. Natural supplements
11.2.6. Phototherapy
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospitals
11.3.2. Research Organizations
11.3.3. Ambulatory Care Centers
11.3.4. Research Organizations
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Pediatric Psoriasis Market – Opportunity Analysis Index, By Type, By Treatment, By End User and Country, 2022 – 2028
11.6. Asia-Pacific Pediatric Psoriasis Market Dynamics – Trends
12. Latin America Pediatric Psoriasis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Plaque psoriasis
12.1.2. Guttate psoriasis
12.1.3. Pustular psoriasis
12.1.4. Inverse psoriasis
12.1.5. Erythrodermic psoriasis
12.1.6. Mucosal/oral psoriasis
12.1.7. Nail psoriasis
12.1.8. Napkin or diaper psoriasis
12.1.9. Photosensitive psoriasis
12.1.10. Flexural psoriasis
12.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Topical therapy
12.2.2. Oral
12.2.3. Injections
12.2.4. Biologics
12.2.5. Natural supplements
12.2.6. Phototherapy
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospitals
12.3.2. Research Organizations
12.3.3. Ambulatory Care Centers
12.3.4. Research Organizations
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Pediatric Psoriasis Market – Opportunity Analysis Index, By Type, By Treatment, By End User and Country, 2022 – 2028
12.6. Latin America Pediatric Psoriasis Market Dynamics – Trends
13. Middle East and Africa Pediatric Psoriasis Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Plaque psoriasis
13.1.2. Guttate psoriasis
13.1.3. Pustular psoriasis
13.1.4. Inverse psoriasis
13.1.5. Erythrodermic psoriasis
13.1.6. Mucosal/oral psoriasis
13.1.7. Nail psoriasis
13.1.8. Napkin or diaper psoriasis
13.1.9. Photosensitive psoriasis
13.1.10. Flexural psoriasis
13.2. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Topical therapy
13.2.2. Oral
13.2.3. Injections
13.2.4. Biologics
13.2.5. Natural supplements
13.2.6. Phototherapy
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospitals
13.3.2. Research Organizations
13.3.3. Ambulatory Care Centers
13.3.4. Research Organizations
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Pediatric Psoriasis Market – Opportunity Analysis Index, By Type, By Treatment, By End User and Country, 2022 – 2028
13.6. MEA Pediatric Psoriasis Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AbbVie Inc.
14.2.2. Amgen Inc.
14.2.3. Eli Lilly & Company
14.2.4. AstraZeneca
14.2.5. Celgene Corporation
14.2.6. Johnson & Johnson
14.2.7. Novartis AG
14.2.8. Merck
14.2.9. Boehringer Ingelheim
14.2.10. LEO Pharma
14.2.11. UCB
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly & Company
  • AstraZeneca
  • Celgene Corporation
  • Johnson & Johnson
  • Novartis AG
  • Merck
  • Boehringer Ingelheim
  • LEO Pharma
  • UCB

Description

Pediatric Psoriasis Market size is valued at USD 11,372.8 million in 2021 and is expected to grow at a CAGR of 8.7% during the forecast period 2022-28. Psoriasis is an autoimmune inflammatory disorder that causes excessive skin cell production, resulting in an itchy, painful skin condition characterized by inflammation, red lesions, and plaque formation. There are mainly two types of psoriasis: plaque psoriasis and psoriatic arthritis (PsA). According to a study published by Celgene Corporation, around 30.0% of patients suffering from the illness develop psoriatic arthritis, which is an inflammation of the joints. The rapidly growing neonatal population born with autoimmune disease, rising prevalence of plaque and psoriatic arthritis, a large pipeline of biologic and biosimilar products, favorable reimbursement policies, and rising biologic product prescription volume are all major factors driving the pediatric psoriasis market growth in the forecast period. According to the National Psoriasis Foundation (NPF), there will be around 125 million psoriasis patients worldwide in 2021. Approximately 14.8% to one-third of all psoriasis cases occur by the age of 15, making this illness a severe global problem. The prevalence of this ailment ranges from 1.5 to 5.0% in most developed countries, with an upward trend linearly from the age of 1-year-old to 18 years old in disease prevalence observed in recent years. The rising incidence of psoriasis around the world has created a significant demand for safe and effective treatment options. Which can be predicted to boost the pediatric psoriasis market size in the prophecy period. For example, according to U.S. Census data, the reported number of cases in the United States in 2021 was roughly 8 million. In addition, MedPage Today, LLC. article published in November 2021 stated that a six-month delay in diagnosing psoriatic arthritis could result in joint erosions, damage, and incapacity. Furthermore, with a thorough analysis of the pediatric psoriasis market insight, it can be estimated that with a recent wave of biologicals in the treatment of psoriatic diseases, FDA approvals of new drugs are predicted to shape the pediatric psoriasis market growth more than expected by the end of 2028, leveraging a considerable market potential for investment in novel product development and clinical trials. Psoriasis is a chronic condition that costs a great deal of money to treat. According to the financial evaluation for psoriasis therapy, medicine expenditures account for around 20.0% of overall costs. According to the NPF, one in every three individuals suffering from the disease has difficulty paying for therapy, and a tube of topical drugs may cost between USD 500 and USD 600. Furthermore, biologics could cost between USD 15,000 and USD 20,000 per year. Thus, despite increased disease prevalence, high medicine prices for treatment and a lack of favorable reimbursement policies in emerging nations are the primary factors limiting market growth over the forecast period.

 

Key Developments in the Pediatric Psoriasis Market:

In July 2022, Arcutis wins FDA endorsement for Zoryve cream in psoriasis treatment in both children and adults

In June 2021, FDA approved Novartis Cosentyx for moderate to severe psoriasis in children and adolescents.

In April 2020, Eli Lilly’s Ixekizumab was approved for pediatric plaque psoriasis treatments.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX